美国 · SEC FORM 4
Q32 Bio Inc.
QTTB · Nasdaq · CIK 0001661998 · Healthcare · Biotechnology
内部人信号
2 位买方 · 4 条买入交易行 · $30.0M 买入总额
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式保持不变。
哪些因素限制了当前分数？
- ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
- ⚠ Purchase activity is becoming less recent
- ✓ 角色得分高 · 买入者中职位最高的是：Director,TenPercentOwner
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
买方广度与集中度
Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.
信号历史
最新留档分数
- 69.1
- 69.0
- 69.0
- 69.0
- 69.0
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -22.2%
- 3M
- -61.0%
- 6M
- +65.1%
- 12M
- +178.9%
波动率与流动性
- 波动率
- 175.3%
- Beta
- —
- 平均每日成交额
- USD 7.7M
估值
- 市值
- USD 248.3M
- P/E
- 8.3×
基本面
- 利润率
- 55.5%
- ROE
- 70.9%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, P/E, 利润率, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-03 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,671,943
- 上期报告
- 3,772,651
- 日均成交量
- 1,084,552
- 回补天数
- 4.3
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
Form 4 申报证据
22 transaction lines in the latest 365-day window; 130 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Violette Shelia M. | 卖出 (S) | Common Stock | 917 | USD 8.32 | USD 7,629 | SEC 申报 ↗ |
| 2026-10-06 | Morrison Jodie Pope | 卖出 (S) | Common Stock | 3,221 | USD 8.32 | USD 26,798 | SEC 申报 ↗ |
| 2026-10-06 | Kalowski Lee | 卖出 (S) | Common Stock | 1,301 | USD 8.32 | USD 10,824 | SEC 申报 ↗ |
展开近期 Form 4 证据 (20 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Violette Shelia M. | 卖出 (S) | Common Stock | 917 | USD 8.32 | USD 7,629 | SEC 申报 ↗ |
| 2026-10-06 | Morrison Jodie Pope | 卖出 (S) | Common Stock | 3,221 | USD 8.32 | USD 26,798 | SEC 申报 ↗ |
| 2026-10-06 | Kalowski Lee | 卖出 (S) | Common Stock | 1,301 | USD 8.32 | USD 10,824 | SEC 申报 ↗ |
| 2026-08-25 | Violette Shelia M. | 卖出 (S) | Common Stock | 2,798 | USD 16.56 | USD 46,335 | SEC 申报 ↗ |
| 2026-08-25 | Morrison Jodie Pope | 卖出 (S) | Common Stock | 9,845 | USD 16.56 | USD 163,033 | SEC 申报 ↗ |
| 2026-08-25 | Kalowski Lee | 卖出 (S) | Common Stock | 3,972 | USD 16.56 | USD 65,776 | SEC 申报 ↗ |
| 2026-07-16 | Violette Shelia M. | 奖励／授予 (A) | Common Stock | 37,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Morrison Jodie Pope | 奖励／授予 (A) | Common Stock | 132,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-16 | Kalowski Lee | 奖励／授予 (A) | Common Stock | 53,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-30 | Manke Isaac | 期权行权／转换 (M) | Common Stock | 53,521 | USD 2.80 | USD 149,859 | SEC 申报 ↗ |
| 2026-05-28 | Xu Diyong | 买入 (P) | Common Stock | 1,875,000 | USD 8.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-05-28 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 1,875,000 | USD 8.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2026-02-25 | Violette Shelia M. | 卖出 (S) | Common Stock | 2,815 | USD 4.51 | USD 12,696 | SEC 申报 ↗ |
| 2026-02-25 | Morrison Jodie Pope | 卖出 (S) | Common Stock | 9,896 | USD 4.51 | USD 44,631 | SEC 申报 ↗ |
| 2026-02-25 | Kalowski Lee | 卖出 (S) | Common Stock | 3,995 | USD 4.51 | USD 18,017 | SEC 申报 ↗ |
| 2026-02-24 | Violette Shelia M. | 奖励／授予 (A) | Common Stock | 37,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-24 | Morrison Jodie Pope | 奖励／授予 (A) | Common Stock | 132,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-24 | Kalowski Lee | 奖励／授予 (A) | Common Stock | 53,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-02 | Morrison Jodie Pope | 卖出 (S) | Common Stock | 22,506 | USD 3.46 | USD 77,871 | SEC 申报 ↗ |
| 2025-12-02 | Kalowski Lee | 卖出 (S) | Common Stock | 9,072 | USD 3.46 | USD 31,389 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | QTTB |
| CIK | 0001661998 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 130 transaction lines from 2020-01-02 to 2026-10-06 4 P purchase lines · 70 S sale lines · 56 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.